Biogen, Inc. is a biotechnology company based in Cambridge, Massachusetts, USA, specializing in the development of neurological diseases, autoimmune diseases, and cancer drugs.

Comanche Biopharma grants Fast Track Status by FDA for CBP-4888, aimed at treating sFlt-1 induced early-onset preeclampsia

This article summarized the latest R&D progress of Hydroxyprogesterone Caproate, the Mechanism of Action for Hydroxyprogesterone Caproate, and the drug target R&D trends for Hydroxyprogesterone Caproate.

Abata Therapeutics reveals the second development candidate, ABA-201, designed for the management of Type 1 Diabetes

Tumor Necrosis Factor (TNF) is a protein produced by immune cells in the human body. It plays a crucial role in regulating inflammation and immune responses.

BeiGene Ltd. is a global biotechnology company founded in 2010 and is one of China's leading innovative pharmaceutical companies.

AusperBio Therapeutics, Inc.have declared today that the FDA has sanctioned the IND application for testing of AHB-137 in clinics.

This article summarized the latest R&D progress of Frovatriptan Succinate, the Mechanism of Action for Frovatriptan Succinate, and the drug target R&D trends for Frovatriptan Succinate.

DPP-4 inhibitors enhance the incretin effect by inhibiting DPP-4.

Founded in 1863 and headquartered in Leverkusen, Germany, Bayer AG is Germany's largest industrial group.

Data analysis from a sample of 822 patients reveals noticeable mepolizumab in symptomatology among Mepolizumab-treated adult asthma sufferers a year post-treatment, regardless of the existence of concomitant medical conditions.

This article summarized the latest R&D progress of Fremanezumab-VFRM, the Mechanism of Action for Fremanezumab-VFRM, and the drug target R&D trends for Fremanezumab-VFRM.